Ocular Therapeutix (OCUL)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from OCUL's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Ocular Therapeutix's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $44M | $51M | $58M | $64M | $52M |
| Net income | -$7M | -$71M | -$81M | -$194M | -$266M |
| Free cash flow | -$67M | -$63M | -$76M | -$136M | -$217M |
| EPS (diluted) | -$0.98 | -$0.97 | -$1.02 | -$1.22 | -$1.42 |
| Operating margin | -179.3% | -152.7% | -141.0% | -269.6% | -519.8% |
Where the revenue comes from
Revenue by products, fiscal 2025. Every breakdown, year by year.
Superinvestors who own OCUL
From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness AQR Capital Management |
Added | $9M | 0.00% | Q2 2026 |
Insider buying
Open-market purchases by Ocular Therapeutix's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Feb 20, 2026 | Richard L Md Lindstrom |
60,229 | $7.66 | $461,354 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when OCUL trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Ocular Therapeutix insiders buying the stock?
1 open-market insider purchase of OCUL in the last 12 months, from SEC Form 4 filings.
Which superinvestors own Ocular Therapeutix?
1 of the superinvestors Investingly tracks hold OCUL in their latest 13F, including Cliff Asness.
Companies like Ocular Therapeutix
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.